Clairvoyant is leading the world’s first trial exploring the use of psilocybin-assisted therapy for alcohol use disorder. In January 2022, they received approval for this Phase II trial from Health Canada. Next to Canada, Clairvoyant is getting national approvals for test sites in Europe (Bulgaria & Finland) for this study. In the trial, participants will receive 25mg of psilocybin or placebo in combination with Motivational Enhancement Therapy (MET) and Psychedelic Specific Therapy (PST).
In November 2021, Clairvoyant closed its initial financing round raising more than $3 million. The bulk of investment came from institutional investors including Inter Investments, Negev Capital and Ambria Capital.
The company is currently doing a $5 million raise at a pre-money valuation of $15 million.
Clairvoyant works together with Fluence to quickly train the therapists for their trials.
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates